PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
29260347-7	2018	Moreover, when apoM+/+ mice were treated with W146, a S1P receptor (S1PR1) antagonist, these inflammatory biomarkers could be significantly upregulated by LPS-induced ALI.	W146	46-50	apolipoprotein M	Mus musculus	15-19
31385019-7	2019	Furthermore, there were significant decreases in the level of S1P-induced COL1A1 expression when the keloid fibroblasts were treated with 30 muM SP600125 or 30 muM PD98059 and that of S1P-induced COL1A1 expression when the treated with 100 nM W146 or 100 nM JTE013 (P < 0.05).	W146	243-247	collagen type I alpha 1 chain	Homo sapiens	74-80
30359564-9	2019	S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings.	W146	64-68	sphingosine-1-phosphate receptor 1	Mus musculus	0-3
29380527-4	2018	We administered vehicle, FTY720 or FTY720+ W146 (an S1P receptor 1 antagonist) to SE rats.	W146	43-47	sphingosine-1-phosphate receptor 1	Rattus norvegicus	52-66
32290092-6	2020	Constitutive barrier stability of HUVEC, but not EA.hy926, was significantly compromised by the S1PR1 antagonist W146 and by the anti-S1P antibody Sphingomab.	W146	113-117	sphingosine-1-phosphate receptor 1	Mus musculus	96-101
30569161-9	2019	Furthermore, the mRNA expression levels of IL-1beta and MCP-1 were significantly elevated following addition of the S1PR1 inhibitor W146, but not by the scavenger receptor class B type I inhibitor, block lipid transport-1 (BLT-1), in apoMTg cells prior to TNF-alpha treatment.	W146	132-136	interleukin 1 beta	Mus musculus	43-51
30569161-9	2019	Furthermore, the mRNA expression levels of IL-1beta and MCP-1 were significantly elevated following addition of the S1PR1 inhibitor W146, but not by the scavenger receptor class B type I inhibitor, block lipid transport-1 (BLT-1), in apoMTg cells prior to TNF-alpha treatment.	W146	132-136	chemokine (C-C motif) ligand 2	Mus musculus	56-61
30569161-9	2019	Furthermore, the mRNA expression levels of IL-1beta and MCP-1 were significantly elevated following addition of the S1PR1 inhibitor W146, but not by the scavenger receptor class B type I inhibitor, block lipid transport-1 (BLT-1), in apoMTg cells prior to TNF-alpha treatment.	W146	132-136	sphingosine-1-phosphate receptor 1	Mus musculus	116-121
30569161-9	2019	Furthermore, the mRNA expression levels of IL-1beta and MCP-1 were significantly elevated following addition of the S1PR1 inhibitor W146, but not by the scavenger receptor class B type I inhibitor, block lipid transport-1 (BLT-1), in apoMTg cells prior to TNF-alpha treatment.	W146	132-136	tumor necrosis factor	Mus musculus	256-265
30476824-9	2019	A S1PR1 antagonist (W146) and NF-kappaB inhibitor (BAY11-7082) inhibited S1P-induced TNF-alpha and IL-1beta secretion and prevented NF-kappaB nuclear translocation.	W146	20-24	sphingosine-1-phosphate receptor 1	Homo sapiens	2-7
30476824-9	2019	A S1PR1 antagonist (W146) and NF-kappaB inhibitor (BAY11-7082) inhibited S1P-induced TNF-alpha and IL-1beta secretion and prevented NF-kappaB nuclear translocation.	W146	20-24	tumor necrosis factor	Homo sapiens	85-94
30476824-9	2019	A S1PR1 antagonist (W146) and NF-kappaB inhibitor (BAY11-7082) inhibited S1P-induced TNF-alpha and IL-1beta secretion and prevented NF-kappaB nuclear translocation.	W146	20-24	interleukin 1 beta	Homo sapiens	99-107
30476824-9	2019	A S1PR1 antagonist (W146) and NF-kappaB inhibitor (BAY11-7082) inhibited S1P-induced TNF-alpha and IL-1beta secretion and prevented NF-kappaB nuclear translocation.	W146	20-24	nuclear factor kappa B subunit 1	Homo sapiens	132-141
29260347-7	2018	Moreover, when apoM+/+ mice were treated with W146, a S1P receptor (S1PR1) antagonist, these inflammatory biomarkers could be significantly upregulated by LPS-induced ALI.	W146	46-50	sphingosine-1-phosphate receptor 1	Mus musculus	54-57
29260347-7	2018	Moreover, when apoM+/+ mice were treated with W146, a S1P receptor (S1PR1) antagonist, these inflammatory biomarkers could be significantly upregulated by LPS-induced ALI.	W146	46-50	sphingosine-1-phosphate receptor 1	Mus musculus	68-73
29140922-8	2018	The antihyperalgesic effects of fingolimod were prevented or reversed by the S1PR1 antagonist W146 (1 mg/kg daily, i.p.)	W146	94-98	sphingosine-1-phosphate receptor 1	Mus musculus	77-82
27671228-6	2017	An S1PR1-selective antagonist, W146, blocked the neuroprotective effects of FTY720.	W146	31-35	sphingosine-1-phosphate receptor 1	Mus musculus	3-8
28970286-6	2017	Treatment with the S1PR1 antagonist W146 or fingolimod and the S1PR1/3 antagonist VPbib2319 decreased baseline and/or S1P-stimulated aldosterone release.	W146	36-40	sphingosine-1-phosphate receptor 1	Rattus norvegicus	19-24
24025642-6	2014	Cultured glomerular endothelial cells treated with a specific S1P1R antagonist (W146) for 3 days also showed reduced HSP27 expression compared with vehicle-treated cells.	W146	80-84	heat shock protein 1	Mus musculus	117-122
25880547-8	2015	Consistent with the siRNA results, pretreatment with W146 and CAY10444, selective antagonists for S1PR1 and S1PR3, respectively, prevented the S1P-induced increase in neuronal excitability.	W146	53-57	sphingosine-1-phosphate receptor 3	Rattus norvegicus	108-113
24876379-4	2014	Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/ neuroprotective cytokines.	W146	45-49	sphingosine-1-phosphate receptor 1	Homo sapiens	28-33
24876379-4	2014	Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/ neuroprotective cytokines.	W146	45-49	interleukin 10	Homo sapiens	106-111
24876379-4	2014	Intrathecal delivery of the S1PR1 antagonist W146 reduced these neuroinflammatory processes but increased IL-10 and IL-4, potent anti-inflammatory/ neuroprotective cytokines.	W146	45-49	interleukin 4	Homo sapiens	116-120
27282481-10	2016	The AUY954-induced eNOS activation was blocked by the S1P1 antagonist W146, the combination of W146 and the S1P3 antagonist CAY10444 and the S1P1,3 antagonist VPC23019, but not by CAY10444 indicating the meaning of S1P1 for the AUY954-induced eNOS activation.	W146	70-74	sphingosine-1-phosphate receptor 1	Homo sapiens	54-58
26597451-7	2016	When S1PR1 was inhibited by using the specific antagonist W146, pro-inflammatory cytokine production declined.	W146	58-62	sphingosine-1-phosphate receptor 1	Gallus gallus	5-10
25880547-8	2015	Consistent with the siRNA results, pretreatment with W146 and CAY10444, selective antagonists for S1PR1 and S1PR3, respectively, prevented the S1P-induced increase in neuronal excitability.	W146	53-57	sphingosine-1-phosphate receptor 1	Rattus norvegicus	98-103
21478479-8	2011	Administration of W146, an S1P1 antagonist, into the renal medulla blocked the effect of FTY720 and decreased the sodium excretion by 37% when infused alone.	W146	18-22	sphingosine-1-phosphate receptor 1	Homo sapiens	27-31
25383272-6	2013	In contrast, pretreatment of (R)-3-amino-4-(3-hexylphenylamino)-4-oxobutyl phosphonic acid (W146), a selective antagonist of S1P1, significantly augments AMD3100-induced KSL-HSPC mobilization into peripheral blood.	W146	92-96	sphingosine-1-phosphate receptor 1	Mus musculus	125-129
22673325-5	2012	Pretreatment with pertussis toxin or the selective S1PR(1) antagonist W146 blocked the sensitization produced by JTE-013.	W146	70-74	sphingosine-1-phosphate receptor 1	Rattus norvegicus	51-58
23723371-9	2013	HDL-induced endothelial cell migration and Akt/eNOS phosphorylation were completely inhibited by the S1P1 antagonist W146 but not by the S1P3 antagonist CAY10444.	W146	117-121	thymoma viral proto-oncogene 1	Mus musculus	43-46
23723371-9	2013	HDL-induced endothelial cell migration and Akt/eNOS phosphorylation were completely inhibited by the S1P1 antagonist W146 but not by the S1P3 antagonist CAY10444.	W146	117-121	sphingosine-1-phosphate receptor 1	Mus musculus	101-105
22992945-10	2012	W146, a known S1P1 receptor antagonist, inhibited the active form of NF-kappaB p65 and COX-2 expression induced by IL-1beta.	W146	0-4	nuclear factor kappa B subunit 1	Homo sapiens	69-78
22992945-10	2012	W146, a known S1P1 receptor antagonist, inhibited the active form of NF-kappaB p65 and COX-2 expression induced by IL-1beta.	W146	0-4	RELA proto-oncogene, NF-kB subunit	Homo sapiens	79-82
22992945-10	2012	W146, a known S1P1 receptor antagonist, inhibited the active form of NF-kappaB p65 and COX-2 expression induced by IL-1beta.	W146	0-4	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	87-92
22992945-10	2012	W146, a known S1P1 receptor antagonist, inhibited the active form of NF-kappaB p65 and COX-2 expression induced by IL-1beta.	W146	0-4	interleukin 1 beta	Homo sapiens	115-123
21798372-0	2011	The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice.	W146	51-55	sphingosine-1-phosphate receptor 1	Mus musculus	4-38
21798372-8	2011	Our study demonstrates that a S1P1 antagonist, W146, induces a significant but transient blood lymphopenia in mice and a parallel increase in CD4+ and CD8+ lymphocytes in lymph nodes.	W146	47-51	sphingosine-1-phosphate receptor 1	Mus musculus	30-34
18708635-9	2008	In addition, lymphopenia induced by CYM-5442 was reversed by W146 administration or upon pharmacokinetic agonist clearance.	W146	61-65	chymosin	Mus musculus	36-39
35144528-11	2022	The S1PR1 antagonist W146 alleviated NTG-induced hyperalgesia and suppressed the upregulation of CGRP, c-fos and pSTAT3 in the TCC.	W146	21-25	sphingosine-1-phosphate receptor 1	Mus musculus	4-9
35144528-11	2022	The S1PR1 antagonist W146 alleviated NTG-induced hyperalgesia and suppressed the upregulation of CGRP, c-fos and pSTAT3 in the TCC.	W146	21-25	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	97-101
35144528-11	2022	The S1PR1 antagonist W146 alleviated NTG-induced hyperalgesia and suppressed the upregulation of CGRP, c-fos and pSTAT3 in the TCC.	W146	21-25	FBJ osteosarcoma oncogene	Mus musculus	103-108